Menchaca, A., Barrera, N., dos Santos Neto, P

Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry Natural GLP-1 in Joint Fluid Shows Potential for Treating Arthritis: The Lancet Denmark: A recent study in The Lancet Rheumatology has identified small amounts of the natural GLP-1 hormone in synovial (joint) fluid, suggesting a potential new role in joint health

Biotin is generally well tolerated, but high levels can interfere with certain lab tests, including some thyroid and cardiac blood work
GLP-1 receptor agonists are uniquely positioned to address several overlapping drivers of disease in HS
(2025, Nature Metabolism ) reported daLUXendin and daLUXendin+, non-lipidated and lipidated dual GLP-1/GIP receptor agonist fluorescent probes with nanomolar affinity at both hGLP1R and hGIPR
Both contain semaglutide, but Wegovy is specifically approved and formulated for weight loss with higher maximum doses (2.4 mg vs 1 mg for Ozempic)